Pfizer and Wyeth have entered into an agreement with Boehringer Ingelheim to divest certain animal health assets, pending Pfizer’s acquisition of Wyeth. Under the agreement, BI will acquire products, research and manufacturing facilities, located in Fort Dodge, IA, as well as related assets and intellectual property, primarily from Wyeth’s Fort Dodge Animal Health portfolio in the U.S. and Canada. Products include cattle and small animal vaccines and some animal health pharmaceuticals. BI also plans to acquire certain animal health assets in other jurisdictions, including animal vaccines in Australia, and cattle vaccines in the EU and South Africa.

The agreement is subject to approval from the U.S. Federal Trade Commission and the Canadian Competition Bureau, and the satisfaction of other customary closing conditions. Pfizer expects to obtain the necessary approvals shortly and expects to close the transaction in 4Q09.

Financial terms of the agreement were not disclosed.